Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.5001
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 135766635600.0
- FreeCF/Share 1.665
- PFCF 14.3684
- PE 17.2285
- Debt/Assets 0.2946
- DivYield 0.0712
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Pfizer discontinues development of weight loss pill
Published: April 14, 2025 by: Proactive Investors
Sentiment: Negative
Pfizer Inc (NYSE:PFE, ETR:PFE) announced it will discontinue the development of its experimental weight-loss pill, danuglipron, due to safety concerns. The company said on Monday that the decision comes after a clinical trial participant experienced a potential drug-induced liver injury, which resolved after stopping the medication.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Pfizer: Anticipating A Game-Changer Soon
Published: April 09, 2025 by: Seeking Alpha
Sentiment: Positive
I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to announce danuglipron updates soon, potentially boosting investor sentiment and stock performance. Pfizer's cost reduction programs and revenue growth targets for CY25 remain on track, with EPS projected to more than double.
Read More
5 Low Price-to-Book Stocks to Add to Your Portfolio in April
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, JD, PFE, STNE and ENS are some such stocks.
Read More
Pfizer: Best-In-Class Dividend Yield Together With Dirt Cheap Valuation
Published: April 09, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's 7.5% dividend yield is safe due to revenue growth, cost efficiency, and a stronger balance sheet, making it a strong buy. Pfizer's innovation in R&D, including AI partnerships and new drug approvals, promises long-term market cap growth and a competitive edge. Defensive stocks like Pfizer are attractive amid market volatility, with the pharmaceutical sector being less vulnerable to economic cycles.
Read More
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Published: April 09, 2025 by: FXEmpire
Sentiment: Negative
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.
Read More
5 Tariff Sell-Off Casualties That Now Pay 7% and Higher Dividends
Published: April 08, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Investors love dividend stocks, especially high-yield varieties, because they offer a significant income stream and have substantial total return potential.
Read More
Is Pfizer (PFE) Stock Undervalued Right Now?
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Read More
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ & PFE expect their sales and profits to improve in 2025.
Read More
Is Pfizer Stock a Buy?
Published: April 03, 2025 by: The Motley Fool
Sentiment: Negative
Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.
Read More
2 Absurdly Cheap Stocks to Buy and Hold for Years
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.
Read More
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Read More
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation
Published: April 02, 2025 by: Reuters
Sentiment: Negative
Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Published: March 31, 2025 by: Fast Company
Sentiment: Negative
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Read More
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
Published: March 26, 2025 by: New York Post
Sentiment: Negative
The report said GSK's former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.
Read More
Here's Why Pfizer (PFE) Fell More Than Broader Market
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
Read More
5 Large Drug Stocks to Watch as Industry Recovers
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Industry Description
Read More
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Of late, pharmaceutical behemoth Pfizer Inc.'s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren't in bad shape either.
Read More
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.
Read More
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
Published: March 20, 2025 by: The Motley Fool
Sentiment: Positive
If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (PFE -0.50%). The pharmaceutical giant isn't as risky an investment as it may appear to be.
Read More
Pfizer to dispose of entire Haleon stake
Published: March 18, 2025 by: Reuters
Sentiment: Neutral
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
Read More
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
Published: March 18, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000